MedTrace Logo

Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients

NCT00928967 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2015-10-09

No results posted yet for this study

Summary

To evaluate the evolution of the impact on daily life activities over the first 12 months following the introduction of interferon beta-1b treatment in patients presenting RRMS or patients at high risk of developing Multiple Sclerosis after a first clinical demyelinating event

Conditions

Interventions

DRUG

Interferon beta-1b, (Betaseron BAY86-5046)

The cohort included is described in section 8.5 (inclusion criteria)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-03-31
Completion
2010-11-30

Countries

  • France

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00928967 on ClinicalTrials.gov